Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised $250 million by offering 11.9 million shares at $21, above the upwardly revised range of $19 to $20. The company originally planned to offer 8.3 million shares at $17 to $19 before increasing the offering to 10 million shares at $19 to $20 on Wednesday.
Cullinan Management plans to list on the Nasdaq under the symbol CGEM. Morgan Stanley, SVB Leerink and Evercore ISI acted as lead managers on the deal.
